Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

Abstract

Objectives of the study were to assess efficacy of tocilizumab in patients with inadequate response to anti TNF in conditions close to clinical practice. Primary outcomes were mostly in safety but also in efficacy.

Monotherapy with TCZ was as effective as combination therapy.

Keywords

• rheumatoid arthritis
• tocilizumab
• biological therapy